BioSpace News Archive

ZyVersa Therapeutics, Inc. announces availability of a new white paper on the critical role of inflammasome ASC in the development and progression of a wide-range of inflammatory diseases.

Civica Inc. announced that biopharma industry veteran Jay Benson has joined Civica as Chief Manufacturing and Supply Chain Officer.

StemBioSys, Inc. announced the launch of CELLvo™ Atrial Cardiomyocyte, a “chamber specific” human induced pluripotent stem cell derived cardiomyocyte designed to function identically to human atrial cardiomyocytes.

Moleculin Biotech, Inc. announced that Walter Klemp, President and Chief Executive Officer and Jonathan Foster, Executive VP and Chief Financial Officer of Moleculin, will present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest on Wednesday, June 21, 2023 at 1:30 PM ET.

Novo Nordisk announced the presentation of 26 abstracts highlighting the breadth of its approved and investigational medicines at the upcoming 83rd Annual Scientific Sessions of the American Diabetes Association.

Charles S. Arnold, Chairman and CEO of Stemtech, stated “in addition to the May 23rd announced Debt Restructuring from our institutional investors over the last month, the company requested that current debt obligations outstanding to myself, as well as board members, management and professional trade creditors convert all their existing debt with the company to equity at the current market.

Zevra Therapeutics, Inc., a rare disease therapeutics company, announced executive management will participate in the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, Tuesday, June 20 through Thursday, June 22, 2023.

NKGen Biotech Inc. announced that they have been invited to give an oral presentation at the 2nd International Alzheimer’s Disease & Dementia Conference 2023 to be held virtually and in-person in Rome, Italy, from June 16–17, 2023.

Cidara Therapeutics, Inc. announced that the company will deliver an oral presentation including highlights from its ongoing preclinical studies of CD421, a CD73-targeting DFC candidate, as well as the development of its novel drug-Fc conjugates from Cidara’s Cloudbreak® platform, at the 2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit in Boston, MA, which is being held June 20-22, 2023.

Jasper Therapeutics, Inc. announced the appointment of Dr. Edwin J. Tucker as Jasper’s Chief Medical Officer.